J Korean Ophthalmol Soc > Volume 56(2); 2015 > Article
Journal of the Korean Ophthalmological Society 2015;56(2):174-179.
DOI: https://doi.org/10.3341/jkos.2015.56.2.174    Published online February 15, 2015.
The Effect of Topical Cyclosporine 0.05% on Tear Osmolarity for Dry Eye Syndrome.
Hyunseung Kang, San Seong, Chul Myong Choe, Se Kyung Kim, Tae Hoon Choi
Nune Eye Hospital, Seoul, Korea. thchoi@hanmail.net
건성안에서 사이클로스포린 0.05% 점안 후 눈물 삼투압의 변화
강현승⋅성 산⋅최철명⋅김세경⋅최태훈
To evaluate the effect of topical cyclosporine 0.05% (Restasis; Allergan, Irving, CA, USA) on tear osmolarity in patients with dry eye disease. METHODS: The present study was a single-center, randomized, prospective, and longitudinal trial. Patients who had been using artificial tears to treat dry eye disease were prescribed cyclosporine 0.05% and evaluated using tear osmolarity, tear break-up time, ocular surface staining score, Schirmer test, and the Ocular Surface Disease Index for symptomatic improvement. Clinical measurements of commonly used objective tests were performed at baseline and after 1, 3, and 6 months. RESULTS: At the end of the study, patients demonstrated statistically significant improvement in tear break-up time (6.26 +/- 1.26 sec at 3 months vs. 4.41 +/- 1.63 sec at baseline, p = 0.022) and OSDI (34.98 +/- 20.19 at 3 months vs. 45.02 +/- 22.38 at baseline, p = 0.032) only at 3 months. Other measures such as Schirmer test, ocular surface grade, and tear osmolarity also showed improvement. However, the differences were not significant. CONCLUSIONS: Over a 6-month period, topical cyclosporine 0.05% showed beneficial effects on symptoms and other commonly used signs of dry eye disease for 3 months; however, the tear osmolarity values were not significantly improved.
Key Words: Cyclosporine;Dry eye syndrome;Restasis;Tear osmolarity

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next